Introduction
Speech and language disorders in humans have a substantial genetic component and likely involve many genes. The forkhead box transcription factor, FoxP2, has been widely studied in this regard since it is mutated and autosomal dominant in developmental verbal dyspraxia (Fisher et al., 1998) , a syndrome involving significant speech and language deficits, as well as broader cognitive dysfunction such as autism spectrum disorder (Feuk et al., 2006) . FoxP2 is highly conserved in vertebrates (Enard et al., 2002) , and the mouse and human orthologs differ by three amino acid changes and an extra glutamine in the human polyglutamine tract. One approach for understanding how FoxP2 might regulate speech and language involves modeling FoxP2 function in animals with defined verbal behaviors such as songbirds and mice. In this regard, mice carrying a null mutation in FoxP2 (Shu et al., 2005) and knock-in mice carrying either a humanized FoxP2 allele (Enard et al., 2009) or human FoxP2 mutations have been generated. Interestingly, mice where FoxP2 is perturbed displayed abnormalities in neonatal ultrasonic vocalization, a stereotypic behavior that is studied as a model for development of human speech and social cognition. However, these mice were also developmentally delayed and exhibited abnormalities in cerebellar development and motor function. It is not yet clear whether these neural abnormalities are the cause of the ultrasonic vocalization deficits and/or how these abnormalities relate to the impaired language development seen in humans.
These studies indicate that FoxP2 plays an important role in neural development, which is perhaps not surprising given the developmental roles played by other members of the same family. For example, FoxP1 defines columnar identity in the spinal cord (Rousso et al., 2008) and regulates outflow tract septation and myocardial proliferation during cardiac development (Wang et al., 2004) . FoxP4 is required for cardiac development, regulating fusion of the bilateral cardiac primordia and subsequent formation of the primitive heart tube (Li et al., 2004b) . In addition, FoxP1 and FoxP2 cooperatively regulate lung airway morphogenesis and differentiation and esophageal muscle development (Shu et al., 2007) . Moreover, FoxP2 and FoxP4 were recently found to regulate neurogenesis in the chick and mouse spinal cord (Rousso et al., 2012) . Thus, the FoxP family regulates development in part by regulating embryonic precursors. In this regard, several studies have shown that FoxP2 mRNA is expressed in the precursor zones of the developing brain (Shu et al., 2001; Ferland et al., 2003 ). Since we have previously shown that perturbations in embryonic neural precursor development likely occur in genetic syndromes that cause cognitive dysfunction (Gauthier et al., 2007; Wang et al., 2010) , we hypothesized that FoxP2 mutations may, at least in part, cause cognitive dysfunction by dysregulating embryonic neurogenesis. Here, we provide evidence for this idea, showing that in the developing mouse cortex FoxP2 knockdown inhibits the transition from radial precursors to in-with the shRNA or overexpression plasmids (total of 4 g of DNA) and 0.5% trypan blue as a tracer. For the rescue experiments, DNA was mixed at a ratio of 1 g of pEF-EGFP:1 g of FoxP2 shRNA: 3 g of human FoxP2 for a total of 5 g of DNA per embryo. For knockdown experiments in which P3 animals were analyzed, DNA was mixed at a ratio of 1 g of PBase:1 g of PB-EGFP: 3 g of FoxP2 shRNA for a total of 5 g of DNA per embryo. The square electroporator CUY21 EDIT (TR Tech) was used to deliver five 50 ms pulses of 40 -50 V with 950 ms intervals per embryo. Except for analysis of neonatal animals, all brains were dissected 3 d post-transfection in ice-cold HBSS. For analysis of neonatal animals, embryos were electroporated from separate litters but pups were born on the same day and brains were harvested at postnatal day 3 (P3). All electroporated brains were fixed in 4% paraformaldehyde (PFA) at 4°C overnight or until they sank to the bottom, cryoprotected, and cryosectioned coronally at 16 m.
Immunocytochemistry and histological analysis. Immunocytochemistry was performed as previously described (Barnabé-Heider et al., 2005) . Briefly, sections were fixed in 4% PFA for 10 min, and then permeabilized and blocked with 5% bovine serum albumin (BSA) and 0.3% Triton-X in PBS for 1 h. Primary antibodies were diluted in the same permeabilization and blocking buffer and incubated either at 4°C overnight or room temperature for 3 h. Secondary antibodies and Hoechst were diluted in PBS. Sections were washed three times for 5 min with PBS between each step. For FoxP2 immunostaining, an antigen retrieval step was added postfixation that involved boiling slides at 92°C in sodium citrate buffer, pH 6, for 20 min. For cultures, 4-well chambers were fixed for 10 min in PFA and then permeabilized with 0.2% NP40 in PBS. Cells were then blocked with 0.5% BSA and 6% normal goat serum or normal donkey serum diluted in PBS. Primary antibodies were diluted in 0.25% BSA and 3% normal goat serum or normal donkey serum in PBS and incubated overnight. Secondary antibodies were diluted in the same blocking solution as primary antibodies and incubated for 1 h. Hoechst was diluted in PBS. The wells were washed with PBS in between each step. The primary antibodies used were mouse anti-GFP (1:1000; Invitrogen), rabbit anti-GFP (1:5000; Abcam), chicken anti-GFP (1:2000; Abcam), mouse anti-␤-III-tubulin (1:1000; Covance), rabbit anti-Pax6 (1:1000; Covance), mouse anti-Pax6 (1:100; Development Studies Hybridoma Bank, The University of Iowa), rabbit anti-Tbr2 (1:1000; Abcam), mouse anti-Satb2 (1:400; Abcam), rabbit anti-cleaved caspase 3 (1:200; Millipore Bioscience Research Reagents), mouse anti-Flag (1:1000; Sigma), goat antiFoxP2 (1:100; Santa Cruz Biotechnology sc-21069). rat anti-Ctip2 (1: 400; Abcam), mouse anti-HuD (1:100; Life Tech), and rabbit anti-Tbr1 (1:1000; Abcam). The secondary antibodies used were Alexa Fluor 555-, Alexa Fluor 488-, and Alexa Fluor 647-conjugated goat or donkey antibodies to mouse, rabbit, or goat IgG (1:1000 for 488/555, 1:500 for 647; Invitrogen). Nuclear staining was performed with Hoechst 33258 (Sigma). In some cases, immunostaining was performed using the MOM Kit (Vector Laboratories), as per manufacturer's instructions.
Western blot analysis. Western blots were performed as described previously (Barnabé-Heider et al., 2005) . Briefly, tissue or cells were harvested and incubated for 30 min at 4°C in radioimmunoprecipitation assay lysis buffer supplemented with 1 mM PMSF, 1 mM Na 3 VO 4 , 10 g/ml aprotenin, and 10 g/ml leupeptin. Lysate was then centrifuged at 13,000 rpm for 10 min and the supernatant was collected. Protein concentration was measured with the BCA Protein Assay Kit (Thermo Scientific). For most experiments, 50 -100 g of lysate was loaded onto each lane of a 10% SDS gel. Proteins were then transferred to nitrocellulose membranes (Bio-Rad) at 250 mA at 4°C overnight (Bio-Rad). Membranes were blocked with 5% skim milk in Tris-buffered saline-Tween 20 (TBST) for 1 h, and incubated with primary antibodies diluted in 5% skim milk in TBST at 4°C overnight. Secondary antibodies were also diluted in 5% skim milk in TBST and incubated for 1 h at room temperature. Three 5 min washes were applied between every step. To develop the blots, membranes were incubated in either ECL or ECL-plus (GE Healthcare) for 5 min and then exposed for varying periods of time. The primary antibodies used were rabbit anti-FoxP2 (Ab #1) (1:1000; Abcam), rabbit anti-FoxP2 (Ab #2) (1:1000; Sigma), goat anti-FoxP2 (Ab #3) (1:1000; Santa Cruz Biotechnology), mouse anti-Flag (1:5000; Sigma), mouse anti-c-myc (1:1000; Santa Cruz Biotechnology), and rab-bit anti-ERK1 K23 (1:5000; Santa Cruz Biotechnology). Secondary antibodies were horseradish peroxidase-conjugated goat anti-mouse or anti-rabbit IgG (1:5000; Boehringer Mannheim).
Flow cytometry. E13 littermate embryos were harvested from crosses between Sox2-EGFP and wild-type B6 mice. EGFP-positive and -negative animals were separated, and cortical cells were harvested as described for the culture experiments, dissociated to single cells in 1% BSA, and sorted for EGFP expression on a MoFlo fluorescent-activated cell sorter (Dako) with viable cells identified by propidium iodide exclusion as previously described (Biernaskie et al., 2009 ). Gates were set using cells isolated from the EGFP-negative cortices.
HEK293 experiments. HEK293 cells were cotransfected with mouse FoxP1, FoxP2, or FoxP4 cDNA and, for the knockdown experiments, with the negative control shRNA or shRNAs against mouse FoxP2. Briefly, cells were plated in 2 ml of DMEM (Lonza) supplemented with 10% fetal bovine serum, 2 M L-glutamine, (Cambrex Biosciences), and 1% penicillin-streptomycin (Invitrogen) in 6-well polystyrene multiwell plates (BD Falcon). The next day, 500 l of Opti-MEM (Invitrogen) and 5 l of Lipofectamine 2000 (Invitrogen) were mixed with the DNA and incubated at room temperature for 30 min. The medium was replaced with 1.5 ml Opti-MEM, and 500 l of the transfection reaction mixture was added. The medium was replaced the next day with DMEM, and cells were harvested 1 or 2 d later for analysis.
Reverse transcription-PCR. Cortices were dissected from embryos and directly subjected to RNA isolation or plated and cultured as described above for the indicated number of days before RNA isolation. Trizol (Invitrogen) was used to isolate RNA according to the manufacturer's protocol. RNA was treated with DNase (Fermentas) to remove any contaminating genomic DNA. Reverse transcription was performed using RevertAid H Minus M-MuLV Reverse Transcriptase (Fermentas) primed with random hexamers, according to the manufacturer's instructions. All reactions were subjected to the following PCR protocol: 94°C for 2 min, 35 cycles of 94°C for 15 s, 58°C for 30 s, and 72°C for 30 s, and a final elongation at 72°C for 2 min. Products were then resolved on a 2% agarose gel.
Microscopy and quantification. For quantification of cell culture experiments, depending on the transfection efficiency, 44 -820 cells per condition per experiment were counted and analyzed using the Zeiss Axioplan2 upright microscope equipped with fluorescence optics. In clonal studies, 28 -210 clones were analyzed per condition per experiment. Clones were defined as groups of EGFP-positive cells in close proximity to each other that were well separated from any other EGFPpositive clusters, but which were not part of distinct unlabeled clusters. Digital image acquisition was performed with Northern Eclipse software (Empix) using a Sony XC-75CE CCD video camera. For quantification of tissue sections, cortical sections were chosen that showed a similar anatomical distribution and amount of EGFP-positive cells for comparison. Brains were sectioned at 16 m at E16/17; three to four brain sections at the same anatomical level per embryo were analyzed using a Zeiss Pascal confocal microscope and the manufacturer's software. A mean of two single optical sections taken with a 40ϫ objective were computed for each image. A total of 3-4 sections was analyzed per embryo by taking up to three 8 -10 mm pictures to cover the electroporated ventricular zone (VZ), subventricular zone (SVZ), and cortical plate (CP) of each coronal section with a 40ϫ objective and comparing them with equivalent sections in littermate control counterparts. For some experiments, sections were instead analyzed using a similar approach with an Olympus IX81 inverted fluorescence microscope equipped with a Hamamatsu C9100-13 back-thinned EM-CCD camera and Yokogawa CSU X1 spinning disk confocal scan head (with Spectral Aurora Borealis upgrade) using Volocity (PerkinElmer) software. Signals were considered to be positive when they were more intense than background labeling, and showed the predicted cellular localization. For measurement of cell location in electroporated cortices, image acquisition was performed using Northern Eclipse Software (Empix) with a Sony-XC-75CE CCD video camera. Ventricular, subventricular, and CP layers were delineated using Hoechst staining. For quantification of FoxP2 overexpression, confocal images were taken as described above. ImageJ was used to quantify immunofluorescent intensity as described in a published study (Burgess et al., 2010) . Briefly, the corrected fluorescence was obtained by subtracting the integrated density by the measured area multiplied by the mean fluorescence background reading, which was determined as an average of three background readings taken of the region adjacent to the cells of interest. Approximately 50 cells from three electroporated embryos each for human versus mouse FoxP2 were measured and the mean fluorescence determined.
Statistics. All data were expressed as the mean Ϯ SEM, and were tested for statistical significance with two-tailed unpaired Student's t tests unless otherwise indicated, in which case they were analyzed with a Student-Neuman-Keuls post hoc ANOVA. Differences were considered significant if p Ͻ 0.05.
Results

FoxP2 is expressed in neural precursors in the embryonic murine cortex
To determine whether FoxP2 is expressed in neural precursors of the embryonic cortex, as suggested by previous in situ hybridization studies (Shu et al., 2001; Ferland et al., 2003; www.genepaint. org; set ID EH3230), we initially analyzed expression of FoxP2 mRNA. Reverse transcription(RT)-PCR of RNA isolated from the murine cortex at E12 demonstrated that FoxP2 mRNA is expressed at this time point (Fig. 1A) , when the cortex is predominantly comprised of precursors. To ask whether the protein is also expressed, we performed Western blot analysis. To do this, we first characterized three different FoxP2 antibodies for their specificity. HEK293 cells were transfected with myc-or flagtagged expression constructs for FoxP1, FoxP2, and FoxP4, all of which are expressed in the embryonic cortex (Shu et al., 2001; Lu et al., 2002) . Western blots of these lysates were then probed with three different FoxP2 antibodies and with antibodies for flag or myc, as relevant. This analysis (Fig. 1B) demonstrated that all three FoxP2 antibodies recognized overexpressed FoxP2, but that two of them also recognized other FoxP family members. We therefore used the third FoxP2-specific antibody to probe Western blots of the embryonic cortex; FoxP2 protein was present at E11, when the cortex does not contain neurons or glial cells, and this expression was maintained throughout embryogenesis, into early postnatal life (Fig. 1C) .
To ask whether FoxP2 is expressed in cortical precursors, as suggested by its early embryonic expression, we performed two additional experiments. First, we analyzed E12 cortical precursor cultures which, when plated, are almost entirely comprised of proliferating radial precursors that go on to generate transitamplifying intermediate progenitors and newly born neurons. RT-PCR and Western blot analysis demonstrated that FoxP2 mRNA and protein were both expressed in these cultures 1 d postplating ( Fig. 1 A, C) . Second, we used flow cytometry to isolate neural precursors from the embryonic cortex, taking advantage of mice where EGFP is knocked-in to the Sox2 locus (Ellis et al., 2004) . In these mice, embryonic radial precursors and intermediate progenitors can be sorted from other cells by virtue of their expression of EGFP (Hutton and Pevny, 2011) . RT-PCR and Western blot analysis of Sox2:EGFP-positive cells isolated from the E13 cortex demonstrated that cortical precursors expressed both FoxP2 mRNA and FoxP2 protein ( Fig. 1 A, C) .
Two classes of precursors are present in the embryonic cortex, radial glial precursors, and intermediate progenitors. To ask which of these two populations express FoxP2, we immunostained the E12/13 cortex with the FoxP2-specific antibody. At this stage, low levels of nuclear FoxP2 were present in most Pax6-positive radial precursors (Fig. 1D ). Tbr2-positive intermediate progenitors also expressed nuclear FoxP2, although this expression was more heterogeneous, with some cells expressing low levels and some higher levels (Fig. 1E) . Similar results were obtained with E12 precursors cultured for 1 d; the most robust levels of nuclear FoxP2 were observed in Tbr2-positive intermediate progenitors, and lower levels were seen in Tbr2-negative radial precursors (Fig. 1F ).
FoxP2 knockdown decreases neurogenesis in the embryonic cortex
To ask about a potential function for FoxP2 in these neural precursors, we generated two shRNAs to knock it down. Western blot analysis of HEK293 cells cotransfected with a mouse FoxP2 overexpression vector and each of the FoxP2 shRNAs showed that these shRNAs robustly decreased FoxP2 protein levels (Fig.  1G ). In contrast, these FoxP2 shRNAs had no effect on the levels of FoxP1 or FoxP4 in similar cotransfection experiments (Fig.  1G) , as predicted by their sequences (FoxP2 shRNA #1 had 13/21 mismatches with FoxP1 mRNA and 12/21 mismatches with FoxP4 mRNA while FoxP2 shRNA #2 had 5/21 and 8/21 mismatches with FoxP1 and FoxP4 mRNAs, respectively). To ask whether these shRNAs were similarly efficacious in cortical precursors, we cotransfected either FoxP2 shRNA #2 or a control shRNA together with a plasmid-expressing EGFP into E12 precursor cultures and immunostained these cultures 3 d later with the FoxP2-specific antibody. Quantification of three independent experiments demonstrated that the number of EGFP-positive cells that expressed bright FoxP2 (as seen in Fig. 1F ) was significantly decreased (control shRNA, 8.0 Ϯ 1.7%, FoxP2 shRNA, 1.5 Ϯ 0.3%; p Ͻ 0.05; n ϭ 3 independent experiments).
Having demonstrated their efficacy, we used these two FoxP2 shRNAs to ask about the biological role of FoxP2 in embryonic cortical precursors. To do this, we electroporated E13/14 cortices with plasmids encoding nuclear EGFP and one of the two shRNAs; this manipulation electroporates embryonic cortical radial precursors, many of which will generate neurons that migrate out of the precursor regions of the cortex (VZ/SVZ) into the CP region. Some of these radial precursors will also generate intermediate progenitors that will then divide and differentiate into neurons. Analysis of cortices at E16/17, 3 d following electroporation, revealed that both of the FoxP2 shRNAs altered the location of EGFP-positive cells relative to a control shRNA (Fig.  2 A, B) . In particular, they caused a significant reduction in the percentage of EGFP-positive cells, presumably newly born neurons, that were present in the CP, and a significant increase in the percentage that remained in the VZ/SVZ (Fig. 2 A, B) .
We asked whether this change in cellular distribution could be due to enhanced cell death by immunostaining sections for EGFP and the apoptotic marker cleaved caspase-3 (CC3) 2 and 3 d postelectroporation. Numbers were similar in control and experimental brains at both time points, averaging ϳ0 -3 cells per section (at 3 d, p Ͼ 0.05 for the comparisons between control vs FoxP2 shRNA#1 and control vs FoxP2 shRNA#2, n ϭ 3 embryos each, five sections per embryo). We then asked whether the changes were due to perturbed neurogenesis by immunostaining sections for the transcription factor Satb2. Satb2 is a marker for one subpopulation of cortical neurons (Alcamo et al., 2008) , and, consistent with this, we found that at E16/17, no Satb2-positive cells coexpressed the intermediate progenitor marker Tbr2 or the radial precursor marker Pax6 (Fig. 2C,D) . Moreover, virtually all of the electroporated, EGFP-positive neurons in the CP expressed Satb2 when cortices were electroporated at E13/14 (Fig.  2 E, F ) . Quantification of electroporated cortical sections immunostained with Satb2 demonstrated that FoxP2 knockdown caused a decrease in the number of neurons that were generated (Fig.   2G) , consistent with the decrease in EGFP-positive cells in the CP (Fig. 2B) . A similar decrease was observed when sections were immunostained for the panneuronal marker HuD (Fig. 2G) .
To ask whether cortical precursors were also altered by FoxP2 knockdown, we immunostained sections for Pax6 and Tbr2, markers for radial precursors and intermediate progenitors, respectively, 3 d following electroporation of the two different FoxP2 shRNAs. This analysis demonstrated that FoxP2 knockdown caused an increase in the proportion of EGFP-positive, Pax6-positive radial precursors (Fig. 3 A, B) and a decrease in the proportion of EGFP-positive, Tbr2-positive intermediate progenitors (Fig. 3C,D) .
These results indicate that the transition from radial precursors to intermediate progenitors and neurons is perturbed by FoxP2 knockdown. To ask whether this perturbation has longlasting consequences for cortical neurogenesis, we used the PB transposon. In this system, a plasmid encoding the PB transposase is cotransfected with a plasmid-encoding EGFP flanked by inverted terminal repeats, and when the transposase is expressed, this leads to genomic integration of the flanked EGFP sequence (Nagy et al., 2011), thereby allowing long-term EGFP expression in the progeny of electroporated radial precursors. We coelectroporated the transiently expressed FoxP2 shRNA together with plasmids encoding PB transposase and the EGFP reporter at E13/ 14, and analyzed cortical neurons at P3. This analysis demonstrated that ϳ80% of EGFP-expressing progeny of electroporated precursors were Satb2-positive neurons, and that transient knockdown of FoxP2 during embryogenesis did not cause longterm alterations in this number (Fig. 3 E, F ) . Immunostaining for two other cortical neuron markers, Tbr1 and Ctip2, demonstrated that only 1-5% of the EGFP-positive cells expressed either of these markers, and that these were unaltered by FoxP2 knockdown ( Fig. 3 E, F ) . However, while the decrease in neuronal number that was observed at E16/17 was lost by P3, potentially due to the transient nature of the FoxP2 knockdown, the localization of these neurons was aberrant (Fig. 3G ). In particular, in contrast to controls, in cortices electroporated with the FoxP2 shRNA, ϳ20% of the NeuN-positive, EGFP-positive neurons were located in layers V and VI (Fig. 3G,H ) , and most of these mislocalized neurons expressed Satb2. This analysis also demonstrated that significantly more transfected Satb2-positive neurons were located in the deep cortical layers following FoxP2 knockdown (Fig. 3G,H ) .
These data indicate that FoxP2 knockdown during embryogenesis perturbs neurogenesis. To ensure that these results are not due to off-target effects of the shRNA, we performed rescue experiments with human FoxP2, which is not targeted by the shRNAs. Specifically, E13/14 cortices were electroporated with plasmids encoding EGFP and FoxP2 shRNA #1 Ϯ a human FoxP2 overexpression vector. Analysis of these cortices 3 d later confirmed that coincident human FoxP2 expression largely reversed the decrease in EGFP-positive cells in the CP and the increase in the VZ/SVZ caused by FoxP2 knockdown (Fig. 4 A, B) . Similarly, immunostaining demonstrated that coincident human FoxP2 expression completely reversed the decrease in Tbr2-positive intermediate progenitors and Satb2-positive neurons and the increase in Pax6-positive radial precursors seen with FoxP2 knockdown (Fig. 4C-E ).
FoxP2 knockdown inhibits the genesis of neurogenic intermediate progenitors
These data indicate that FoxP2 knockdown delays the progression from radial precursors to intermediate progenitors and neu-rons in vivo. To characterize this phenotype further, we knocked down FoxP2 in culture; radial precursors were isolated from the E12 cortex, and upon plating were cotransfected with a control shRNA or with FoxP2 shRNA #2 plus an EGFP expression construct. Initially we characterized these cultures for apoptosis and proliferation. Immunostaining for CC3 demonstrated that FoxP2 knockdown had no significant effect on the low proportion of CC3-positive apoptotic cells (Fig. 4F ) . In contrast, immu- nostaining for the proliferation marker Ki67 demonstrated that FoxP2 knockdown caused a significant increase from ϳ60 to 80% in the proportion of proliferating cells (Fig. 4F ) .
To ask whether this increase in proliferation reflected an increase in self-renewing radial precursors, as suggested by the in vivo knockdown data, we performed clonal analysis using the PB transposon. Specifically, E12 precursors were cotransfected with FoxP2 shRNA #2 plus or minus a human FoxP2 overexpression construct together with plasmids encoding PB transposase and the PB EGFP reporter construct, under conditions where only a small number of cells were transfected. We then analyzed the size and composition of EGFP-positive clones in these cultures (Fig.  4G ). This analysis showed that FoxP2 knockdown caused a significant increase in the size of the EGFP-positive clones (Fig. 4H ) , with a decrease in single cell clones, and an increase of almost threefold in the proportion of clones containing nine or more cells (Fig. 4I ) . Moreover, only a very small number of control clones contained Ͼ17 cells, but ϳ10% of the FoxP2 knockdown clones were 17 cells or larger (Fig. 4H ) . Importantly, coexpression of human FoxP2 reversed this increase in clone size (Fig.  4 H, I ). We also performed an additional control for the single cell clonal analysis, transfecting cells with a control shRNA together with human FoxP2. This control group was statistically similar to the FoxP2 shRNA plus human FoxP2 group ( p Ͼ 0.05) and was significantly higher than the FoxP2 shRNA plus empty vector group ( p Ͻ 0.01; n ϭ 3 independent experiments for both comparisons).
We also asked about clone composition by immunostaining these cultures for ␤-III-tubulin and Tbr2 (Fig. 4J ) . FoxP2 knockdown increased by ϳ30% the proportion of EGFP-positive clones that did not contain ␤-III-tubulin or Tbr2-positive cells, and this increase in radial precursor clones was significantly reversed by coincident expression of human FoxP2 ( p Ͻ 0.01 for both comparisons, n ϭ 3 independent experiments). Moreover, quantification showed that the FoxP2 but not control shRNA decreased the genesis of intermediate progenitors and neurons, and that these decreases were also reversed by coincident overexpression of human FoxP2 (Fig. 4 K, L) . Together, these data indicate that FoxP2 knockdown in culture enhanced radial precursors at the expense of intermediate progenitors and neurons. Moreover, the increased proliferation observed in culture following FoxP2 knockdown (Fig. 4F ) suggests that the increase in radial precursors observed following FoxP2 knockdown in vivo (Fig. 3B ) may also be due, in part, to enhanced proliferation.
Ectopic expression of human but not mouse FoxP2 promotes the radial precursor to intermediate progenitor transition in the mouse cortex
These data indicate that FoxP2 knockdown decreases genesis of intermediate progenitors from radial precursors. Since a number of groups have suggested that evolutionary changes in mammalian FoxP2 might be important (Enard et al., 2002; Krause et al., 2007; Konopka et al., 2009 ), we asked whether mouse and human FoxP2 proteins had similar or different activities when ectopically expressed in radial precursors. To do this, we used flagtagged expression constructs for mouse and human FoxP2 (Konopka et al., 2009 ) that were identical except that one encoded mouse and the other human FoxP2 coding sequences (Fig.  5A) . We verified that these constructs were expressed at similar levels by transfecting them into HEK293 cells, and probing equal amounts of protein on Western blots with either the FoxP2 antibody or with an antibody for the flag tag (Fig. 5B) .
We then introduced these constructs into cortical precursors in vivo, electroporating them into the E13/14 cortex along with a nuclear EGFP expression plasmid. Three days later we demonstrated that both constructs were expressed by staining cortical sections either for the flag tag present on the tagged proteins or for FoxP2 itself. Flag-tagged murine and human FoxP2 were both detectably expressed in EGFP-positive cells (Fig. 5C) . Moreover, image analysis of sections immunostained for FoxP2 (Fig. 5D ) demonstrated that mouse and human FoxP2 were expressed at similar levels in electroporated precursors (mouse FoxP2 levels were set to 1.0; mouse FoxP2, 1.0 Ϯ 0.28, human FoxP2, 1.0 Ϯ 0.17; p ϭ 0.99, n ϭ 3 embryos each). Since both proteins were expressed in electroporated precursors, we asked whether they affected cortical precursor biology. Immunostaining for EGFP (Fig. 5E ) demonstrated that the distribution of transfected cells was similar in cortices electroporated with the control vector and mouse FoxP2 ( p Ͼ 0.05; n ϭ 3 embryos each), but that electroporation with human FoxP2 caused a small but significant decrease in the proportion of electroporated cells in the VZ/SVZ relative to controls (control vector, 31.6 Ϯ 2.6, human FoxP2, 26.0 Ϯ 1.0; p Ͻ 0.05, n ϭ 4 embryos each). To ask whether this reflected a change in precursor composition, we immunostained these sections for EGFP and Pax6 or Tbr2. Quantification demonstrated that human FoxP2 overexpression decreased the proportion of Pax6-positive radial precursors and increased the proportion of Tbr2-positive intermediate progenitors (Fig. 5F ) relative to controls. In contrast, mouse FoxP2 had no effect on the proportions of these two precursor types (for Pax6-positive cells, control vector, 20.3 Ϯ 0.8%, mouse FoxP2, 20.0 Ϯ 3.4%, p ϭ 0.94; for Tbr2-positive cells, control vector, 16.8 Ϯ 0.8%, mouse FoxP2, 17.1 Ϯ 1.8%, p ϭ 0.87; n ϭ 3 embryos each).
To more definitively establish these differences between human and mouse FoxP2 proteins, we performed similar studies electroporating different embryos in the same mothers with human versus mouse FoxP2 constructs. We then analyzed these cortices 3 d later by immunostaining for Pax6 and Tbr2. Quantification showed that human and mouse FoxP2 overexpression had significantly different effects, with human FoxP2 causing a decrease in Pax6-positive radial precursors and an increase in the percentage of Tbr2-positive intermediate progenitors relative to mouse FoxP2 (Fig. 5G) .
Since human FoxP2 increased the number of neurogenic intermediate progenitors, we asked whether it also altered the number or phenotype of cortical neurons. To ask about neuron number, we analyzed cortices 3 d postelectroporation at E16/17. Immunostaining for EGFP and HuD demonstrated a small but significant increase in the proportion of EGFP-positive cortical neurons (Fig. 6A) . A similar small but significant increase was observed when sections were immunostained for Satb2 (control vector, 42.3 Ϯ 4.8, human FoxP2, 52.6 Ϯ 4.8; p ϭ 0.03, two-tailed paired Student's t test, n ϭ 4 embryos each). To ask about neuronal phenotypes, we analyzed cortices postnatally, electroporating embryos at E13/14 with plasmids encoding EGFP and human FoxP2, and immunostaining them for different neuronal markers at P3 (Fig. 6 B, C) . Quantification showed that human FoxP2 did not significantly affect the proportion of Satb2-positive neu- rons at this longer time point nor did it affect the small number of Ctip2 or Tbr1-positive neurons (Fig. 6D) .
To further explore the possibility that human, but not mouse, FoxP2 enhances the transition from radial precursors to intermediate progenitors when ectopically expressed in the mouse, we performed similar experiments in culture, cotransfecting mouse versus human FoxP2 constructs together with an EGFP expression plasmid into cultured radial precursors. Clonal analysis 4 d later showed that human FoxP2 caused a decrease in clone size, significantly increasing the proportion of one cell clones relative to either mouse FoxP2 or the empty vector (Fig. 6 E, F ) . Consistent with this, immunostaining showed that human, but not mouse FoxP2 increased the proportion of Tbr2-positive intermediate progenitors (Fig. 6G) and ␤-III-tubulin-positive neurons (Fig. 6H ) that were generated in these cultures. Thus, human FoxP2 apparently acts as a gain-of-function protein in murine cortical precursors, acting to promote the radial precursor to intermediate progenitor transition and enhance neurogenesis.
The human FoxP2 KE mutation acts like a dominant-inhibitory FoxP2 protein
Since our data indicate that even the small differences between human and murine FoxP2 proteins can alter its ability to regulate neural precursor development, we asked about a mutant FoxP2 protein that has been implicated in aberrant vocalization. To do this, we examined a FoxP2 mutation from the KE family (Lai et al., 2001 ) using a flag-tagged expression construct identical to that used for the human versus mouse overexpression studies. This mutation results in a FoxP2 protein carrying a single amino acid switch in the forkhead DNA binding domain (Fig. 5A) . Cotransfection into HEK293 cells demonstrated that the KE mutant was expressed at levels similar to the normal human FoxP2 protein (Fig. 5B) . We then cotransfected cultured cortical precursors with plasmids encoding nuclear-localized EGFP and the wild-type or mutant human FoxP2 or murine FoxP2, and immunostained them 1 d later for EGFP and the flag tag. This analysis (Fig. 7A ) demonstrated that all three proteins were expressed, but that their localization differed. In particular, the normal murine and human FoxP2 proteins were limited to nuclei, colocalizing closely with nuclear EGFP (Fig. 7A) . In contrast, the human KE mutant was present in both the cytoplasm and nucleus (Fig. 7A) . Quantification showed that Ͼ60% of the flag-positive cells transfected with the KE mutant expressed detectable FoxP2 in the cytoplasm (Fig. 7B) .
These experiments indicate that the mutant human FoxP2 protein is expressed at readily detectable levels in cortical precursors, but that it is aberrantly localized. These data are consistent with previous reports expressing it in cell lines (Vernes et al., 2006; Mizutani et al., 2007) , which showed that the KE mutant protein was present in the cytoplasm and that it even caused aberrant localization of wild-type FoxP2 protein in the cytoplasm. We therefore electroporated the E13/14 cortex with expression plasmids for the KE mutant protein and EGFP, and analyzed precursor development 3 d later. Immunostaining for EGFP demonstrated that location of transfected cells within the cortex was perturbed by expression of the mutant FoxP2, with significantly more cells present in the VZ/SVZ and significantly fewer in the CP relative to the empty vector (Fig. 7C,D) . Coincident with this change in location, there was an increase in the proportion of Pax6-positive radial precursors and a decrease in Tbr2-positive intermediate progenitors (Fig. 7E) . There was also a trend toward a decrease in Satb2-positive neurons, but this did not reach significance (Fig. 7E) . Thus, in contrast to human FoxP2, the KE mutant FoxP2 protein decreased the radial precursor to intermediate progenitor transition thereby phenocopying the FoxP2 knockdown phenotype, suggesting that it was functioning as a dominant-inhibitory protein.
To further explore the possibility that the KE mutant FoxP2 has a different phenotype from normal human FoxP2 protein, we overexpressed it in cultured cortical precursors for 4 d. Consistent with the idea that the KE mutant protein inhibited cortical precursor differentiation, clonal analysis demonstrated that it increased clone size relative to human and murine FoxP2 proteins (Fig. 6 E, F ) . Moreover, immunostaining demonstrated that there were only approximately half as many Tbr2-positive intermediate progenitors (Fig. 6G) and ␤-III-tubulin-positive neurons (Fig. 6H ) generated from cells that expressed the mutant human FoxP2 compared with normal human FoxP2. Overexpression of the KE mutant also caused a decrease in neurons relative to the empty vector and murine FoxP2 overexpression (Fig. 6H ) , thereby phenocopying the FoxP2 knockdown data (Fig. 4H ) . Together with the in vivo studies, these data provide support for the idea that the human KE mutant acts as a dominant-inhibitory FoxP2 protein.
Discussion
Our results suggest a novel role for the FoxP2 transcription factor in developing neural precursors that may have implications for evolution of a larger mammalian cortex. In this regard, our findings support three major conclusions. First, our data indicate that FoxP2 is expressed in developing cortical precursors, and that when it is knocked down, this perturbs the genesis of intermediate progenitors and neurons from multipotent radial precursors. Second, our data indicate that human and mouse FoxP2 proteins differ with regard to their ability to regulate the genesis of intermediate progenitors when ectopically expressed. When mouse FoxP2 is overexpressed either in vivo or in culture, this has no effect on cell genesis, indicating that mouse FoxP2 is not sufficient to promote the genesis of intermediate progenitors, and suggesting that it is normally not limiting for neural precursors. However, when human FoxP2 is overexpressed in the same way, this enhances the genesis of intermediate progenitors and neurons, indicating that human FoxP2 acts as a gain-of-function protein relative to murine FoxP2. This is an intriguing result, given the high homology between these two orthologs. Third, our data indicate that the KE mutant FoxP2, which acts as an autosomal dominant gene in humans, functions as a dominantinhibitory protein with regard to neurogenesis. Specifically, we show that, as seen previously in cell lines, this mutant FoxP2 is localized to both the nucleus and cytoplasm in cortical precursors, and that it phenocopies FoxP2 knockdown when overex- pressed, causing increased radial precursors and decreased intermediate progenitors and neurons. Together, these findings suggest a novel proneurogenic role for FoxP2 and, from a broader context, suggest that genetically defined changes in proteins like FoxP2 may contribute to the evolution of the human cortex.
The FoxP2 gene has garnered significant interest because it is mutated in a monogenic syndrome causing speech and language dysfunction (Lai et al., 2001) . This relationship has led to speculation that small changes in FoxP2 sequence are causally related to the evolution of human speech (Enard et al., 2002; Zhang et al., 2002; Vernes et al., 2007) . In support of this idea, human FoxP2 has transcriptional targets that are distinct from mouse and even chimpanzee FoxP2 (Vernes et al., 2007 (Vernes et al., , 2011 Konopka et al., 2009) , and corticobasal circuitry is functionally different in a immunostained for EGFP (green), Tbr1 (red), and Satb2 (blue). Scale bar, 400 m. C, Confocal micrographs of coronal cortical sections of electroporated brains at P3 immunostained for EGFP (green) and Ctip2 (red). Scale bar, 400 m. D, Quantification of sections similar to those in B and C for the percentage of EGFP-positive cells that were also positive for Satb2 (left two bars), Tbr1 (middle two bars), or Ctip2 (right two bars). p Ͼ 0.05; n ϭ 3 animals each. E-H, E12 cortical precursor cultures were cotransfected with an EGFP plasmid and expression constructs for mouse FoxP2 (mFoxP2), wild-type human FoxP2 (hFoxP2), or human FoxP2 carrying the KE mutation (hFoxP2-R553H or KE FoxP2). As a control, cultures were cotransfected with the empty vector (Control). E, Quantification of the sizes of transfected EGFP-positive clones. mouse where two of the human amino acid changes are knocked-in to the mouse FoxP2 allele (Enard et al., 2009; Reimers-Kipping et al., 2011) . Thus, the few amino acid changes between the different FoxP2 proteins are clearly important and are likely somehow involved in functional neural differences between species. In this regard, though, it is still unclear whether FoxP2 is only important for speech and language and/or whether it plays a broader role in neural function.
Previous studies on FoxP2 have used the songbird (Haesler et al., 2007) and the mouse (Shu et al., 2005; French et al., 2007; as models for understanding how this gene might regulate vocalization. Work in both models has shown that FoxP2 is expressed in neurons, and that depletion of FoxP2 leads to changes in vocalization (Shu et al., 2005; French et al., 2007; and neuronal morphology (Vernes et al., 2011) . In this regard, knock-out mice and mice homozygous for mutant human FoxP2 alleles are developmentally delayed, die within several weeks of birth, display perturbed ultrasonic vocalizations, and have smaller brains with a particularly small cerebellum. While these neural phenotypes are thought to be due to perturbed neuronal connectivity, the results presented here suggest that they are, in part, due to aberrant neurogenesis. Strong additional support for this conclusion comes from a recent study that placed FoxP2 and FoxP4 together in a proneurogenic pathway (Rousso et al., 2012) . This study showed that Foxp2 is initially expressed throughout the neuroepithelium, and that inactivation of FoxP2 and FoxP4 function led to neuroepithelial disorganization and enhanced maintenance of neural precursors, a result consistent with the findings reported here.
How then does FoxP2 regulate neurogenesis? During cortical development, neurons are generated either directly from radial glial precursors or indirectly via intermediate progenitors. Intriguingly, the number of intermediate progenitors correlates with cortical expansion (Martinez-Ceredeño et al., 2006) and the intermediate progenitor population is enhanced in humans relative to rodents (Hansen et al., 2010) . Moreover, deletion of genes required for intermediate progenitors results in decreased cortical thickness and neuron number (Farkas et al., 2008; Sessa et al., 2008) . In this regard, our knockdown data argue that FoxP2 promotes neurogenesis in part by enhancing the genesis of intermediate progenitors from radial precursors. Intriguingly, our expression data also show that while FoxP2 is expressed at low levels in radial precursors, its expression is robustly increased in at least a subset of intermediate progenitors. Thus, one interpretation of our data is that FoxP2 levels normally increase as part of a prointermediate progenitor gene expression program, and that when we knock it down in radial precursors, this prevents this induction and inhibits the transition. However, our data showing that overexpression of mouse FoxP2 in these same radial precursors does not cause them to prematurely generate intermediate pro- genitors argues that increased FoxP2 is necessary but not sufficient for this transition.
What are the molecular mechanisms that allow FoxP2 to regulate the radial precursor to intermediate progenitor transition? First, in the recent Rousso et al. (2012) paper, the authors show that ectopic expression of FoxP2 downregulates expression of N-cadherin, a key component of apical adherens junctions. Since radial precursors, but not intermediate progenitors, are part of the apical epithelium, then perhaps a FoxP2-mediated delamination from this epithelium is a key part of the transition between these two cell types. Second, FoxP2 can directly inhibit transcription of the DISC1 gene (Walker et al., 2012) , and suppression of DISC1 causes developing neural precursors to stop proliferating and to differentiate (Mao et al., 2009 ). Third, FoxP2 regulates transcription of the autism-associated gene CNTNAP2, which is expressed in neural precursors, and regulates neuronal development (Peñagarikano et al., 2011) . Thus, FoxP2 may regulate these and other downstream targets to promote neurogenesis.
One intriguing result presented here is that human FoxP2 acts as a gain-of-function protein within the murine context. These data imply that the four amino acid changes that distinguish the human and mouse proteins enhance the proneurogenic actions of FoxP2. While we do not yet know which amino acid change accounts for this difference, the amino acid switch at position 324 of mouse FoxP2 (homologous to position 325 of human FoxP2) introduces a consensus protein kinase C (PKC) phosphorylation site into the human FoxP2 protein. In this regard, we recently showed that atypical PKCs regulate cortical neurogenesis (Wang et al., 2012) , and PKCs are activated in neural precursors by neurotransmitters, peptide ligands, and growth factors (Canoll et al., 1996; Ma et al., 2000; Hansel et al., 2001; Song and Ghosh, 2004) . Moreover, this particular amino acid substitution is one of two that have been knocked-in to the mouse FoxP2 gene, and shown to result in alterations in corticobasal ganglia circuits (Enard et al., 2009; Reimer et al., 2011) . Regardless of the underlying mechanism, these findings indicate that FoxP2 evolved an enhanced proneurogenic function coincident with evolution of a larger cortex. Since recent work suggests that an increase in intermediate progenitors was important for evolution of a larger human cortex (Noctor et al., 2007; Pontious et al., 2008) , then this raises the possibility that a more active FoxP2 was perhaps somehow involved in facilitating this evolution.
One final conclusion arising from these studies is that the KE mutant FoxP2 acts as a dominant-inhibitory protein with regard to neurogenesis, consistent with the autosomal dominant genetics of the KE family (Fisher et al., 1998) . How might it do this? We report here that the KE mutant FoxP2, which is mutated at a single amino acid in the forkhead DNA binding domain, localizes to both the nucleus and cytoplasm of cortical precursors. A similar cytoplasmic localization was seen with this mutant in cell lines (Vernes et al., 2006; Mizutani et al., 2007) , and cytoplasmic aggregates of this protein were observed in neurons when it was knocked-in to the murine FoxP2 locus . Since the KE mutant FoxP2 can modify the localization of wild-type FoxP2 (Mizutani et al., 2007) , then we propose that it acts as a dominant-inhibitory protein by binding to the endogenous protein and sequestering it in the cytoplasm. It may also mediate this dominant-inhibition function in part by inhibiting appropriate DNA binding and transcriptional activation within the nucleus.
In summary, our findings support a novel role for FoxP2 in developmental neurogenesis, and indicate that human FoxP2 acquired an enhanced ability to promote neurogenesis coincident with the evolution of a larger human cortex. While our findings do not preclude a later role for FoxP2 in neuronal development, we propose that perturbations in the numbers or timing of cortical neuron genesis would ultimately cause aberrant neural circuit formation, thereby potentially providing a neural template for the deficits in speech and language seen in individuals with FoxP2 mutations.
